|
US5916588A
(en)
*
|
1984-04-12 |
1999-06-29 |
The Liposome Company, Inc. |
Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
|
|
US6090406A
(en)
*
|
1984-04-12 |
2000-07-18 |
The Liposome Company, Inc. |
Potentiation of immune responses with liposomal adjuvants
|
|
JPH0832637B2
(ja)
*
|
1985-02-14 |
1996-03-29 |
アクゾ・エヌ・ヴエー |
合成免疫原
|
|
DE3601136A1
(de)
*
|
1986-01-16 |
1987-07-23 |
Max Planck Gesellschaft |
Hemmstoffe der reversen transkriptase fuer prophylaxe und therapie von retrovirus-infektionen in saeugetieren
|
|
US4803070A
(en)
*
|
1986-04-15 |
1989-02-07 |
Ribi Immunochem Research Inc. |
Immunological emulsion adjuvants for polysaccharide vaccines
|
|
US5554372A
(en)
*
|
1986-09-22 |
1996-09-10 |
Emory University |
Methods and vaccines comprising surface-active copolymers
|
|
US6054438A
(en)
*
|
1987-01-07 |
2000-04-25 |
Imperial Cancer Research Technology Limited |
Nucleic acid fragments encoding portions of the core protein of the human mammary epithelial mucin
|
|
US5466714A
(en)
*
|
1987-12-31 |
1995-11-14 |
Research Foundation For Mental Health Hygiene, Inc. |
Spermicidal and cytocidal fatty acid compositions
|
|
US5434182A
(en)
*
|
1987-12-31 |
1995-07-18 |
Isaacs; Charles E. |
Antibacterial fatty acid compositions
|
|
US4997851A
(en)
*
|
1987-12-31 |
1991-03-05 |
Isaacs Charles E |
Antiviral and antibacterial activity of fatty acids and monoglycerides
|
|
EP0324455A3
(en)
*
|
1988-01-15 |
1991-03-27 |
Hans O. Ribi |
Novel polymeric immunological adjuvants
|
|
AU4338189A
(en)
*
|
1988-09-23 |
1990-04-18 |
University Of Southern California |
Immunotherapy vaccine for melanoma tumors
|
|
FI902821A7
(fi)
*
|
1989-06-12 |
1990-12-13 |
Res Foundation For Mental Hygiene |
Infektion leviämisen vähentäminen verenkäsittelylaitteistolla
|
|
DE4007315A1
(de)
*
|
1990-03-08 |
1991-09-12 |
Behringwerke Ag |
Verwendung von zink-calciumhydroxid, lecithin und pao zur adjuvierung von antigenloesungen und auf diese weise adjuvierte antigenloesungen
|
|
US5091188A
(en)
*
|
1990-04-26 |
1992-02-25 |
Haynes Duncan H |
Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
|
|
US5246707A
(en)
*
|
1990-04-26 |
1993-09-21 |
Haynes Duncan H |
Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdroplets and high-concentration liposomes
|
|
IE920860A1
(en)
|
1991-03-19 |
1992-09-23 |
Cytrx Corp |
Polyoxypropylene/polyoxyethylene copolymers with improved¹biological activity
|
|
ATE183099T1
(de)
*
|
1991-04-19 |
1999-08-15 |
Lds Technologies Inc |
Konvertierbare mikroemulsionsverbindungen
|
|
US5688761A
(en)
*
|
1991-04-19 |
1997-11-18 |
Lds Technologies, Inc. |
Convertible microemulsion formulations
|
|
IL105325A
(en)
*
|
1992-04-16 |
1996-11-14 |
Minnesota Mining & Mfg |
Immunogen/vaccine adjuvant composition
|
|
FR2702373B1
(fr)
*
|
1993-03-08 |
1996-06-07 |
Rhone Merieux |
Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
|
|
NZ263538A
(en)
*
|
1993-03-23 |
1996-10-28 |
Smithkline Beecham Biolog |
Vaccine compositions of 3-o-deacylated monophosphoryl lipid a
|
|
DE69433013T2
(de)
*
|
1993-05-27 |
2004-06-03 |
Entremed, Inc. |
Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten
|
|
US5718904A
(en)
*
|
1995-06-02 |
1998-02-17 |
American Home Products Corporation |
Adjuvants for viral vaccines
|
|
US5690942A
(en)
*
|
1995-06-02 |
1997-11-25 |
American Home Products Corporation |
Adjuvants for viral vaccines
|
|
DE69637441T2
(de)
*
|
1995-10-17 |
2009-03-05 |
Jagotec Ag |
Verabreichung unlöslicher arzneistoffe
|
|
US6465016B2
(en)
|
1996-08-22 |
2002-10-15 |
Research Triangle Pharmaceuticals |
Cyclosporiine particles
|
|
US7255877B2
(en)
*
|
1996-08-22 |
2007-08-14 |
Jagotec Ag |
Fenofibrate microparticles
|
|
US5849307A
(en)
*
|
1997-03-26 |
1998-12-15 |
The Picower Institute For Medical Research |
Vaccine adjuvant
|
|
US6455323B1
(en)
|
1997-07-03 |
2002-09-24 |
Pharmacia & Upjohn Company |
Anti-bacterial methods and materials
|
|
CA2320807C
(en)
*
|
1998-02-11 |
2011-01-18 |
Research Triangle Pharmaceuticals |
Method and composition for treatment of inflammatory conditions
|
|
US6979456B1
(en)
|
1998-04-01 |
2005-12-27 |
Jagotec Ag |
Anticancer compositions
|
|
CA2333648C
(en)
|
1998-05-29 |
2008-10-21 |
Rtp Pharma Inc. |
Thermoprotected microparticle compositions and process for terminal steam sterilization thereof
|
|
AU759641B2
(en)
*
|
1998-08-19 |
2003-04-17 |
Skyepharma Canada Inc. |
Injectable aqueous dispersions of propofol
|
|
GB2348203B
(en)
|
1998-11-04 |
2002-06-19 |
Imp College Innovations Ltd |
Solube beta-forms of prion proteins, methods of preparation and use
|
|
BR9915738A
(pt)
*
|
1998-11-20 |
2001-10-02 |
Rtp Pharma Inc |
Micropartìculas estabilizadas em fosfolipìdeos dispersìveis
|
|
EP1860117A3
(en)
|
1999-04-09 |
2008-09-03 |
Pharmacia & Upjohn Company LLC |
Anti-bacterial vaccine compositions
|
|
US6790950B2
(en)
|
1999-04-09 |
2004-09-14 |
Pharmacia & Upjohn Company |
Anti-bacterial vaccine compositions
|
|
IL148685A0
(en)
*
|
1999-09-21 |
2002-09-12 |
Rtp Pharma Inc |
Surface modified particulate compositions of biologically active substances
|
|
NZ521425A
(en)
|
2000-03-17 |
2004-05-28 |
Upjohn Co |
Vaccine comprising a first attenuated non-reverting mutant Salmonella in which two or more secretion system apparatus genes have been inactivated
|
|
EP1360315A2
(en)
|
2000-04-06 |
2003-11-12 |
PHARMACIA & UPJOHN COMPANY |
Antimicrobial methods and materials
|
|
WO2001080828A2
(en)
|
2000-04-20 |
2001-11-01 |
Rtp Pharma Inc. |
Improved water-insoluble drug particle process
|
|
US7323174B1
(en)
|
2000-06-12 |
2008-01-29 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Modulation of immune response and methods based thereon
|
|
CA2420597C
(en)
|
2000-08-31 |
2011-05-17 |
Rtp Pharma Inc. |
Milled particles
|
|
NZ525231A
(en)
*
|
2000-09-20 |
2004-08-27 |
Skyepharma Canada Inc |
Phospholipid stabilised feno-fibrate microparticles for pharmaceutical use
|
|
US8586094B2
(en)
*
|
2000-09-20 |
2013-11-19 |
Jagotec Ag |
Coated tablets
|
|
AU2001259099B2
(en)
*
|
2001-02-22 |
2005-12-22 |
Skyepharma Canada Inc. |
Fibrate-statin combinations with reduced fed-fasted effects
|
|
FR2824279B1
(fr)
*
|
2001-05-04 |
2004-05-28 |
Seppic Sa |
Emulsion e/h concentree
|
|
GB0112126D0
(en)
|
2001-05-18 |
2001-07-11 |
Allergene Inc |
Composition
|
|
FR2824269B1
(fr)
*
|
2001-09-03 |
2012-03-02 |
Seppic Sa |
Composition adjuvante constituee de 1% a 15% de tensioactifs a hlb global compris entre 5 et 8 et de 85% a 99% de corps gras
|
|
US8193185B2
(en)
|
2003-01-21 |
2012-06-05 |
Novartis Vaccines And Diagnostics, Inc. |
Use of tryptanthrin compounds for immune potentiation
|
|
US7893096B2
(en)
|
2003-03-28 |
2011-02-22 |
Novartis Vaccines And Diagnostics, Inc. |
Use of small molecule compounds for immunopotentiation
|
|
GB0315323D0
(en)
|
2003-07-01 |
2003-08-06 |
Royal Veterinary College |
Vaccine composition
|
|
US9023366B2
(en)
|
2003-07-01 |
2015-05-05 |
The Royal Veterinary College |
Vaccine composition for vaccinating dogs against canine infectious respiratory disease (CIRD)
|
|
EP2277595A3
(en)
|
2004-06-24 |
2011-09-28 |
Novartis Vaccines and Diagnostics, Inc. |
Compounds for immunopotentiation
|
|
US20110104186A1
(en)
|
2004-06-24 |
2011-05-05 |
Nicholas Valiante |
Small molecule immunopotentiators and assays for their detection
|
|
US20060210590A1
(en)
|
2005-02-03 |
2006-09-21 |
Alk-Abello A/S |
Minor allergen control to increase safety of immunotherapy
|
|
EP2010537B1
(en)
*
|
2006-03-23 |
2011-12-28 |
Novartis AG |
Imidazoquinoxaline compounds as immunomodulators
|
|
EP2010530A2
(en)
*
|
2006-03-23 |
2009-01-07 |
Novartis AG |
Methods for the preparation of imidazole-containing compounds
|
|
US8063063B2
(en)
*
|
2006-03-23 |
2011-11-22 |
Novartis Ag |
Immunopotentiating compounds
|
|
WO2009039628A1
(en)
|
2007-09-27 |
2009-04-02 |
Immunovaccine Technologies Inc. |
Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
|
|
US20100209452A1
(en)
*
|
2007-10-03 |
2010-08-19 |
Immunovaccine Technologies, Inc |
Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
|
|
CN102056622B
(zh)
*
|
2008-06-05 |
2016-04-06 |
免疫疫苗技术有限公司 |
包含脂质体、抗原、多核苷酸和含疏水物质的连续相的载体的组合物
|
|
EA026557B1
(ru)
|
2008-12-09 |
2017-04-28 |
Джилид Сайэнс, Инк. |
Промежуточные соединения для получения модуляторов толл-подобных рецепторов
|
|
CN102300483B
(zh)
|
2010-01-29 |
2015-08-19 |
株式会社御木本 |
装饰品用卡扣
|
|
WO2011143617A1
(en)
|
2010-05-14 |
2011-11-17 |
Baxter International Inc. |
Chimeric ospa genes, proteins, and methods of use thereof
|
|
WO2012010290A1
(en)
|
2010-07-21 |
2012-01-26 |
Athera Biotechnologies Ab |
Diagnostic and therapeutic methods and compositions for metabolic disease
|
|
WO2012010291A1
(en)
|
2010-07-21 |
2012-01-26 |
Athera Biotechnologies Ab |
Diagnostic and therapeutic methods and compositions for metabolic disease
|
|
EP2462950A1
(en)
|
2010-12-08 |
2012-06-13 |
Neovacs |
Strongly inactivated and still highly immunogenic vaccine, and process of manufacturing thereof
|
|
AU2011340477A1
(en)
|
2010-12-08 |
2013-06-20 |
Neovacs |
Strongly inactivated and still highly immunogenic vaccine and process of manufacturing thereof
|
|
EP2508197A1
(en)
|
2011-04-07 |
2012-10-10 |
Neovacs |
Method for treating IFNalpha related conditions
|
|
PT2694094T
(pt)
|
2011-04-07 |
2017-11-06 |
Neovacs |
Método para tratar afeções relacionadas com ifn alfa
|
|
WO2013049941A1
(en)
|
2011-10-06 |
2013-04-11 |
Immunovaccine Technologies Inc. |
Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof
|
|
GB201200259D0
(en)
|
2012-01-09 |
2012-02-22 |
Ohlin Per M |
Novel therapies
|
|
CN104640563A
(zh)
|
2012-07-27 |
2015-05-20 |
巴克斯特国际公司 |
包含嵌合的ospa分子的组合物及其使用方法
|
|
WO2016001907A1
(en)
|
2014-07-02 |
2016-01-07 |
Prendergast Patrick T |
Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
|
|
EP3613764A1
(en)
|
2014-10-15 |
2020-02-26 |
Xenothera |
Composition with reduced immunogenicity
|
|
CN112512590A
(zh)
|
2018-06-04 |
2021-03-16 |
阿普罗斯治疗公司 |
Tlr7肽缀合物
|
|
CA3103503A1
(en)
|
2018-07-02 |
2020-01-09 |
Ayuvis Research, Inc. |
Novel immunodulating small molecules
|
|
EP3922255A1
(en)
|
2020-06-10 |
2021-12-15 |
Prokarium Limited |
Cancer therapy
|
|
GB202009411D0
(en)
|
2020-06-19 |
2020-08-05 |
Prokarium Ltd |
Autotransporter systems
|
|
CN112807426A
(zh)
*
|
2021-01-26 |
2021-05-18 |
郭志文 |
一种基于动物疫苗的聚合物佐剂、制备方法及其应用
|
|
EP4124342A1
(en)
|
2021-07-28 |
2023-02-01 |
Prokarium Limited |
Cancer therapy with live attenuated bacteria
|
|
JP2024536733A
(ja)
|
2021-09-07 |
2024-10-08 |
ユニベルシテ デ トゥール |
コロナウイルス融合タンパク質
|
|
GB202215134D0
(en)
|
2022-10-13 |
2022-11-30 |
Prokarium Ltd |
Composition
|
|
GB202215576D0
(en)
|
2022-10-21 |
2022-12-07 |
Prokarium Ltd |
Circuit
|
|
WO2025068401A1
(en)
|
2023-09-28 |
2025-04-03 |
Prokarium Limited |
Interleukin 15 variant
|
|
WO2025068413A1
(en)
|
2023-09-28 |
2025-04-03 |
Prokarium Limited |
Interleukin 18 variants
|
|
WO2025109155A1
(en)
|
2023-11-24 |
2025-05-30 |
Prokarium Limited |
Interleukin variant
|
|
WO2025224251A1
(en)
|
2024-04-24 |
2025-10-30 |
Prokarium Limited |
Modified microorganisms
|
|
GB202405780D0
(en)
|
2024-04-24 |
2024-06-05 |
Prokarium Ltd |
Vacuole escape
|